-$0.36 Earnings Per Share Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter

Analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce earnings per share of ($0.36) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.40). AVEO Pharmaceuticals reported earnings per share of ($0.33) in the same quarter last year, which suggests a negative year over year growth rate of 9.1%. The company is scheduled to issue its next quarterly earnings results on Monday, November 8th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($1.58). For the next fiscal year, analysts forecast that the business will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.68) to $0.32. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.05. The company had revenue of $7.56 million during the quarter, compared to analyst estimates of $7.76 million. AVEO Pharmaceuticals had a negative net margin of 398.34% and a negative return on equity of 107.25%.

AVEO has been the topic of several research reports. HC Wainwright cut their price target on shares of AVEO Pharmaceuticals from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, July 12th. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 4th. One analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $15.33.

AVEO stock traded down $0.44 during mid-day trading on Wednesday, reaching $6.45. 14,483 shares of the stock traded hands, compared to its average volume of 1,217,686. The stock has a market capitalization of $221.71 million, a PE ratio of -3.32 and a beta of 1.20. AVEO Pharmaceuticals has a one year low of $4.95 and a one year high of $18.24. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.39 and a current ratio of 6.39. The business has a 50-day moving average price of $5.87 and a two-hundred day moving average price of $6.87.

In other news, CEO Michael P. Bailey purchased 15,000 shares of the company’s stock in a transaction on Wednesday, September 1st. The shares were purchased at an average price of $6.48 per share, with a total value of $97,200.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 3.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in AVEO. Eudaimonia Partners LLC bought a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $48,000. Blueshift Asset Management LLC purchased a new stake in AVEO Pharmaceuticals during the second quarter valued at $67,000. Laurion Capital Management LP purchased a new stake in shares of AVEO Pharmaceuticals in the first quarter valued at $73,000. Verition Fund Management LLC purchased a new position in AVEO Pharmaceuticals in the 1st quarter worth about $84,000. Finally, The Manufacturers Life Insurance Company bought a new position in AVEO Pharmaceuticals during the 1st quarter worth about $97,000. 41.69% of the stock is owned by hedge funds and other institutional investors.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E.

Featured Article: Quick Ratio

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.